Clinico-laboratory and immunological characteristics of patients with compensated cirrhosis of the liver in the outcome of chronic hepatitis C on the background of treatment with a direct antiviral drug paritrapeprir/ritonavir/ombitasvir/ dasabuvir

Abstract

Goal. Paritrapeprir / ritonavir / ombitasvir / dasabuvir on the clinical and laboratory parameters, including the subpopulation composition of lymphocytes, in patients with compensated cirrhosis in the outcome of chronic hepatitis C. Materials and methods. The study included patients with compensated liver cirrhosis class A (no more than 6 on the Child – Turcotte – Pugh scale), in the outcome of chronic hepatitis C, genotype 1b (group 1, n = 28). The comparison group (group 2, n = 25) consisted of patients comparable in terms of gender and main study parameters, not receiving antiviral therapy. Results. A stable virologic response was 96,8%. There were no serious adverse events requiring treatment reversal. As a result of treatment, there was a disappearance or a significant decrease in the severity of asthenovegetative and dyspeptic syndromes, a reduction in liver size, an improvement in liver functional parameters (biochemical response), and normalization of the balance of the cellular immunity by increasing CD3 +, CD4 +, CD8 + – CD16 + lymphocyte counts. The conclusion. Etiotropic therapy with paritrapeprir /ritonavir / ombitasvir / dasabuvir is well tolerated by patients with compensated cirrhosis in the outcome of chronic hepatitis C, has high efficacy, positively influences the dynamics of clinical manifestations, and also helps reduce the imbalance of the cellular immunity.

Keywords

• chronic hepatitis c
• liver cirrhosis
• directacting antiviral agents
• subpopulations of lymphocytes